While San Diego remains the center of the industry, Los Angeles-area companies are growing
Why is Sobi paying $950M upfront for Arthrosi? Analyze the deal terms, the $550M in milestones, and the projected growth through the 2030s.
Amgen acquires Dark Blue Therapeutics to fight Acute Myeloid Leukemia. See how this $840M deal aims to deliver first-in-class AML treatments.
Fulgent Genetics agrees to buy StrataDx and assets from Bako Diagnostics for $55.5 million. Learn how this cash deal expands their pathology capabilities.
Can the immune system cure cancer? Dr. Patrick Soon-Shiong discusses a paradigm shift using NK cells to treat tumors without chemotherapy.
Novartis will acquire Avidity Biosciences for $12 billion at $72 per share, gaining its RNA-targeting platform and neuroscience pipeline as Avidity spins off its precision cardiology programs into a new public company.
Kite, a life science company based in Santa Monica, will acquire Interius BioTherapeutics for $350 million to advance the development of in vivo CAR therapies.
Valencia-based biotech firm SetPoint Medical has raised $140 million in private financing to support the commercialization of its neuroimmune modulation therapy for rheumatoid arthritis.
Learn how Varda is pioneering “Zero-G Biology.” The space tech company just raised $187M to expand its mission of creating pharmaceuticals in low-Earth orbit.
Top experts from Amgen, CBIZ & Intrepid discuss 2025 trends in healthcare, biotech, and life sciences. Explore key insights on AI, VC funding, and valuations.
